Miller Richard A MD's Form 4 filing
Corvus Pharmaceuticals, Inc. (CRVS) · filed May 20, 2026
- Accession no.
- 0001610717-26-000160
- Filed
- May 20, 2026
- Trade date
- May 18, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $83.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Miller Richard A MDCIK 0001031847 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Common Stock | PPurchaseAcquired | +5,000 | $12.05 | +$60,250 | 1,193,103 | Indirect | |
| May 18, 2026 | Common Stock | PPurchaseAcquired | +1,932 | $12.01 | +$23,203.32 | 1,195,035 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.